Miderix (Methocarbamol, Paracetamol)

Methocarbamol acts centrally to depress spinal reflexes, easing muscle tension, while paracetamol inhibits central cyclooxygenase activity, lowering prostaglandin production and providing analgesic and antipyretic effects. Together they target both pain and spasm.

The dosage of Miderix is determined by the prescribing clinician based on the patient’s condition, age, weight and response. The prescriber will set the appropriate strength, frequency and duration according to clinical guidelines.

Safety of Miderix in pregnancy or lactation has not been fully established. Healthcare professionals should evaluate the risk‑benefit ratio and consider alternative therapies. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their doctor.

To request Miderix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miderix offers a fixed‑dose combination of methocarbamol and paracetamol, providing both muscle relaxation and analgesia in a single tablet. Compared with separate prescriptions, it may simplify dosing and improve adherence, though clinicians should consider individual drug tolerability and specific patient needs when selecting therapy.

Miderix should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Miderix is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, blood‑cell disorders and anaphylaxis. Patients should seek immediate medical attention if they notice rash, jaundice, unexplained bruising, or signs of an allergic reaction.

Miderix should be avoided in individuals with known hypersensitivity to methocarbamol, paracetamol or any excipients in the formulation. It is also contraindicated in patients with severe liver disease, uncontrolled asthma, or those taking interacting CNS depressants without medical supervision.